What is Pearl AI doing strategically?

Pearl launched Pearl Voice on April 8, 2026, adding ambient listening, AI-generated clinical notes in SOAP and dental-specific formats, voice-enabled perio charting, and direct PMS write-back. The product covers the full appointment, not just the X-ray review window.

A vendor present at every billable touchpoint in an appointment is structurally harder to displace than a vendor present at one. Pearl Voice changes the renewal conversation from 'how accurate is your AI on X-rays' to 'how much of your documentation workflow runs through us.' That is a stickier question for a DSO clinical operations buyer.

This is the most consequential Pearl move in the past twelve months. It is not a feature add. It is a deliberate expansion of the session footprint that makes Pearl's ACV per location harder to cut without losing multiple workflows at once. If voice adoption sticks, their per-location revenue compounds and their churn risk drops.

PDS Health (1,100-plus practices nationwide) selected Pearl as enterprise AI partner in February 2026. DECA Dental Group (nearly 200 practices across nine states) deployed Pearl organization-wide following a successful pilot in February 2026. Both are named exclusive partnerships.

Exclusivity agreements inside large DSOs do not just generate revenue. They remove those locations from any competitive evaluation for the contract term. Two major DSOs going exclusive in the same quarter signals that Pearl's enterprise sales motion is working, not experimenting. The mid-market DSO segment will watch these announcements and treat them as social proof.

The pace matters as much as the names. Two enterprise exclusivity deals inside a single quarter means Pearl's DSO pipeline is converting, not stalling. Founders pitching DSO clinical directors need a clear answer to 'why not just use Pearl' before the conversation gets to a demo.

In December 2025, the FDA granted Pearl 510(k) clearance for AI-powered pathology detection on panoramic radiographs, covering caries, periapical radiolucencies, and impacted third molars. This extended Second Opinion's cleared coverage to the most widely used extraoral imaging modality in dentistry.

Each FDA clearance Pearl adds is a barrier that competitors must match before they can credibly sell into regulated DSO procurement processes. DSO clinical directors increasingly require FDA clearance as a baseline procurement criterion, not a differentiator. For early-stage dental AI founders, this means the regulatory timeline is a real cost that must be budgeted from the first product decision.

Pearl now holds clearances across bitewing, periapical, panoramic, and CBCT modalities. That breadth is difficult to replicate quickly and expensive to challenge on regulatory grounds alone. Compete on a surface where clearance is not the primary buying criterion, or plan your own regulatory timeline now.